Sumitomo Dainippon Pharma Co., Ltd., its U.S.-based subsidiary Sunovion Pharmaceuticals Inc. and Otsuka Pharmaceutical Co., Ltd. announce today that we have executed a collaboration and license agreement for worldwide joint development and commercialization of the following four novel candidate compounds (hereinafter referred to as the "four compounds") currently under development in psychiatry and neurology area by Sumitomo Dainippon Pharma and Sunovion.

The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces today the launch of Otsuka’s Digital Pioneer Initiative (ODPI). The ODPI was created to accelerate Otsuka’s digital health capabilities through active and strategic engagement with early-stage companies focused on improving mental health and well-being.  MSRD also announced a strategic investment in Mindful Mamas—a digital solution for maternal and family mental wellness.

With gender inequality a continued area of focus for corporations and workplaces around the globe, the Healthcare Businesswomen’s Association (HBA) is proud to recognize Otsuka America Pharmaceutical, Inc., and Merck & Co., Inc., for exemplary workplace initiatives working to close the gender gap in the healthcare and life science industries. The awards will be presented on Wednesday, November 10, 2021, in conjunction with HBA’s virtual Annual Conference.

The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces today that it has entered an agreement with Sentinel Oncology (Sentinel), a drug discovery company.

The McQuade Center for Strategic Research and Development at Otsuka in the U.S. will support the clinical development of a first-in-class therapeutic with the potential to treat Fragile X syndrome (FXS), a rare, genetic condition that causes intellectual disability, behavioral and learning challenges, and various physical characteristics¹.

PRINCETON, NJ – The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces today that it has entered an agreement with Aché Laboratórios Farmacêuticos S.A. (Aché), a leader in the Latin American pharmaceutical market, to co-develop a therapy with the potential to treat general anxiety disorder (GAD) and post-traumatic stress disorder (PTSD).

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces topline outcomes from a phase II clinical trial that evaluated the safety and efficacy of brexpiprazole for the treatment of patients with borderline personality disorder (BPD). 

The Sozosei Foundation, a charitable foundation funded by Otsuka America Pharmaceutical, Inc., awarded $100,000 to the American India Foundation (AIF) COVID-19 Response Fund. This grant is drawn from Sozosei’s Disaster Relief and Recovery Philanthropy Program in response to India’s state of emergency, as the country records the highest number of cases and virus-related deaths globally.

Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), a subsidiary of Otsuka Pharmaceutical Co., Ltd., announces that it has been awarded a grant for up to $17.8 million from the Bill & Melinda Gates Foundation. This will enable Otsuka to advance clinical trials of its investigational compound OPC-167832, in combination with its delamanid (DELTYBA^® is the brand name where approved outside the U.S.) and Johnson & Johnson’s bedaquiline (SIRTURO^® is the brand name), for patients with drug-susceptible pulmonary tuberculosis (DS-TB).

Otsuka Pharmaceutical Development & Commercialization, Inc., announces that it has entered a three-year collaboration with Holmusk Inc., a global data science and digital health company building the world’s largest real-world evidence (RWE) platform for behavioral health.

The Sozosei Foundation, a charitable foundation funded by Otsuka America Pharmaceutical, Inc., awarded grants to 10 organizations committed to the decriminalization of mental illness by ensuring the effective implementation of 988 as the nationwide mental health crisis hotline that goes live in July, 2022 and by increasing access to mental healthcare in communities across the United States.